HLAVNÍ TÉMA SGLT-2 inhibitory a jejich uplatnění v praxi – update 2022 | 103 / Vnitř Lék. 2022;68(2):96-103 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz ke snížení mortality, úhrada gliflozinů v indikaci léčby chronického onemocnění ledvin je tedy pouze otázkou času. Revoluční přínos SGLT2i je proto silně vnímán nejen diabetology, ale i kardiology, nefrology a internisty. U pacientů s diabetem 2. typu s klíčovými komorbiditami (srdeční selhání, chronické onemocnění ledvin, vysoké a velmi vysoké kardiovaskulární riziko) musí být indikace gliflozinů s prokázanými neglykemickými benefity zvažována vždy bez ohledu na kompenzaci diabetu, respektive hodnotu glykovaného hemoglobinu, a glifloziny by v takovém případě měly být preferovány nad antidiabetiky s pouze glykemickým působením. LITERATURA 1. Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine. 1998;15(7):539-553. 2. World Health O. Global Report on Diabetes. Global Report on Diabetes, 2016. 3. Nwaneri CH Cooper, Bowen‑Jones D. Mortality in type 2 diabetes mellitus: Magnitude of the evidence froma systematic review andmeta‑analysis. British Journal of Diabetes and Vascular Disease. 2013;13(4):192-207. 4. Cubbon RM et al. Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non‑ischaemic aetiology. Diabetes and Vascular Disease Research. 2013;10(4):330-336. 5. MacDonald MR et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure - An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal. 2008;29(11):1377-1385. 6. Matsushita K et al. Association of estimated glomerular filtration rate and albuminuria with all‑cause and cardiovascular mortality in general population cohorts: a collaborative meta ‑analysis. The Lancet. 2010;375(9731):2073-2081. 7. Reidy K et al. Molecular mechanisms of Diabetic kidney disease. Journal of Clinical Investigation. 2014;124(6):2333-2340. 8. Iborra‑Egea O et al. Unraveling the Molecular Mechanismof Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes. JACC Basic Transl Sci. 2019;4(7):831-840. 9. Zinman B et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine. 2015;373(22):2117-2128. 10. Neal B et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine. 2017;377(7):644-657. 11. Wiviott SD et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine. 2019;380(4):347-357. 12. Cannon CP et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. New England Journal of Medicine. 2020;383(15):1425-1435. 13. Perkovic V et al. Canagliflozin and renal outcomes in type 2 diabetes: results fromthe CANVAS Program randomised clinical trials. The Lancet Diabetes and Endocrinology. 2018;6(9):691-704. 14. Neal B et al. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‑R): A randomized, placebo‑controlled trial. Diabetes, Obesity and Metabolism. 2017;19(3):387-393. 15. Neal B et al. Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‑R trials. Diabetes, Obesity and Metabolism. 2017;19(7):926-935. 16. Kosiborod M et al. Lower risk of heart failure and death in patients initiated on sodium ‑glucose cotransporter-2 inhibitors versus other glucose‑lowering drugs: The CVD‑REAL study (Comparative Effectiveness of Cardiovascular Outcomes in NewUsers of Sodium‑Glucose Cotransporter-2 Inhibitors). Circulation. 2017;136(3):249-259. 17. Kosiborod M et al. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose‑Lowering Drugs: The CVD‑REAL 2 Study. Journal of the American College of Cardiology. 2018;71(23):2628-2639. 18. Udell JA et al. Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: Results from the EASEL population‑based cohort study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world). Circulation. 2018;137(14):1450-1459. 19. Patorno E et al. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis from the EMPRISE Study. Circulation. 2019;139(25): 2822-2830. 20. McMurray JJV et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. 21. Abraham WT et al. Rationale and design of the EMPERIAL‑Preserved and EMPERIAL ‑Reduced trials of empagliflozin in patients with chronic heart failure. European Journal of Heart Failure. 2019;21(7):932-942. 22. Packer M et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine. 2020;383(15):1413-1424. 23. Anker SD et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine. 2021;385(16):1451-1461. 24. Voors AA et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature Medicine. 2022. 25. Herrington WG et al. The potential for improving cardio‑renal outcomes by sodium ‑glucose co‑transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA‑KIDNEY study. Clinical Kidney Journal. 2018;11(6):749-761. 26. Jardine MJ et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. American journal of nephrology. 2017;46(6):462-472. 27. Heerspink HJL et al. Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 2020;383(15):1436-1446. 28. McMurray John JV et al. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. JACC: Heart Failure. 2021;9(11):807-820. 29. Davies MJ et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461-2498. 30. Buse JB et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020;63(2):221-228. 31. ADA, Standards of Medical Care in Diabetes–2022. Diabetes Care. 2021. 45(Supplement_1) 32. Cosentino F et al. 2019 ESC Guidelines on diabetes, pre‑diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre‑diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). European Heart Journal. 2019;41(2):255-323. 33. Authors/Task Force M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24(1):4-131.
RkJQdWJsaXNoZXIy NDA4Mjc=